Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-12-20, Stock:ABBV, The news for the past five days is as follows:
2019-12-13: NEWS1: Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019 (Revised).NEWS2: Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020.NEWS3: 5 Cheap Dividend Stocks With High Yields And Annual Increases.NEWS4: Retirees Should Know These 3 Facts About Required Minimum Distributions - December 13, 2019.NEWS5: Walgreens, AbbVie, and 3 Other Dividend Aristocrat Stocks That Have Lagged the Market This Year.
2019-12-16: NEWS1: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.NEWS2: How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - December 16, 2019.
2019-12-17: NEWS1: Morphic Holding Tabbed as Likely to Develop Blockbuster Drug.
2019-12-18: NEWS1: AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL).NEWS2: AbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis.NEWS3: AbbVie’s Humira Sales in Europe Appear to Be Holding Up Better Than Anticipated.NEWS4: ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway.
2019-12-19: NEWS1: AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU.

Answer: Rise